Immune Score Based Radiomics in Nasopharyngeal Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Immune Score Based Radiomics.
- Who it may be relevant to
- Registry conditions: Nasopharyngeal Carcinoma. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)
Overview
In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.
Interventions
- Diagnostic test Immune Score Based Radiomics
To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
Primary outcome measures
- Area Under Curve (AUC) [Time frame: Median follow-up time of 5 years for the whole group]
Eligibility criteria
Inclusion criteria
Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.
ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC >4\*109/L, HGB>90G/L, and PLT>100\*109/L. Written informed consent
Exclusion criteria
Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), or emotional disturbance.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 5 centers
- Renmin Hospital of Wuhan University — Wuhan
- Ningbo First Hospital — Ningbo
- Ningbo Medical Center Lihuili Hospital — Ningbo
- The First Affiliated Hospital of Wenzhou Medical University — Wenzhou
- Zhejiang Cancer Hospital — Hangzhou
Identifiers
NCT: NCT05126160 · ZJCH-2021-NPC01